Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • blessbuilding blessbuilding Apr 16, 2014 2:13 AM Flag

    Alnylam outlook not affected by Novartis decision, says JMP

    From investorvillage: "ALNY: Alnylam outlook not affected by Novartis decision, says JMP

    Alnylam outlook not affected by Novartis decision, says JMP Securities
    After Novartis (NVS) discontinued its RNAi drug discovery program, JMP
    Securities does not think the decision should affect the potential of Alnylam's
    (ALNY) pipeline. The firm believes that Novartis' inability to figure out RNAi
    technology - and not problems with RNAi as a whole - led to Novartis' decision.
    The firm reiterates a $110 price target and Outperform rating on Alnylam."

    Sentiment: Strong Buy

 
ALNY
68.41+1.60(+2.39%)Jul 27 4:00 PMEDT